FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
South San Francisco, CA — December 14, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …
Home »
Risk for MCI Up With Progressive Cerebral Small Vessel Disease
FRIDAY, Jan. 4, 2019 — Patients with hypertension with progression of periventricular white matter hyperintensities have an increased risk for …